Top 5 pediatric health headlines you missed in April 2026

In this monthly recap, Contemporary Pediatrics reviews the most significant developments shaping pediatric practice and public health. Click each title below for full coverage.

1. AAD issues pediatric atopic dermatitis guidelines for optimal patient care

The American Academy of Dermatology published its first clinical guidelines for the prevention and management of atopic dermatitis in patients younger than 18 years, emphasizing pediatric-specific considerations in safety, dosing, and caregiver involvement. The guidance notes limited evidence for prevention strategies, with only moisturizers receiving a conditional recommendation for reducing disease onset in young children, while dietary and environmental interventions showed no clear benefit.

For treatment, the guidelines outline an expanded range of options, including topical corticosteroids as first-line therapy, along with calcineurin inhibitors, phosphodiesterase-4 inhibitors, topical Janus kinase inhibitors, aryl hydrocarbon receptor agonists, phototherapy, and systemic agents such as monoclonal antibodies for moderate to severe disease. Conditional recommendations are also provided for supportive measures such as bathing, wet wrap therapy, and phototherapy. Overall, the guidelines aim to support individualized, evidence-based care and improve quality of life for pediatric patients and their families.

2. Guideline updates management of recurrent wheezing in infants

A consensus guideline from the China Medical Education Association outlines a structured approach to the diagnosis, treatment, and long-term management of recurrent wheezing in infants and toddlers, addressing a heterogeneous condition with limited diagnostic clarity in children younger than 3 years. Developed using a modified Delphi process and systematic literature review, the recommendations emphasize distinguishing wheezing phenotypes and identifying underlying etiologies—such as viral infections, early childhood asthma, and protracted bacterial bronchitis—through detailed clinical history, physical examination, and targeted ancillary testing.

Management strategies are stratified by disease phase and severity, with short-acting β-agonists recommended as first-line therapy for acute episodes and inhaled corticosteroids for severe exacerbations or high-risk patients, while routine antibiotic and systemic corticosteroid use is discouraged. During remission, maintenance inhaled corticosteroids may be considered for select patients, alongside environmental control measures and longitudinal follow-up to account for evolving disease patterns.

3. Nirsevimab linked to lower RSV hospitalization risk in high-risk infants

A nationwide case-control analysis from Chile found that nirsevimab was associated with substantial reductions in respiratory syncytial virus (RSV)–related lower respiratory tract infection hospitalizations among at-risk infants, including those born preterm or with congenital heart disease. Using linked national registry data from the 2024 RSV season, investigators reported an 84.3% reduction in hospitalization risk among at-risk infants and an 85.1% reduction among high-risk infants, with the greatest observed effect in those with congenital heart disease.

Population-level modeling suggested that universal infant immunization with nirsevimab reduced RSV-related hospitalizations by 71.5% compared with a projected palivizumab-only strategy, corresponding to hundreds of hospitalizations averted. Safety findings from passive surveillance identified no new safety signals. These real-world data extend prior clinical trial evidence and support the use of single-dose nirsevimab as a broader preventive strategy for RSV in high-risk infant populations.

4. Measles vaccination coverage remains below herd immunity after postelimination outbreak

A repeated cross-sectional study presented at the Pediatric Academic Societies 2026 Meeting found that measles-mumps-rubella (MMR) vaccination coverage remained below herd immunity thresholds up to 20 months after a postelimination outbreak in central Ohio, with only modest improvements observed across a large primary care network.

Among more than 133,000 children, timely first-dose MMR coverage remained low at approximately 53.6% with no meaningful change over time, while second-dose and overall coverage increased slightly but remained suboptimal for preventing sustained transmission.

Disparities persisted, with children of Somali descent demonstrating significantly lower first-dose coverage compared with peers. The findings indicate that outbreak-related public health interventions alone may be insufficient to close underlying immunity gaps and highlight the need for sustained, targeted vaccination strategies to improve early immunization and reduce the risk of future measles transmission.

5. Arcutis submits sNDA for roflumilast cream 0.05% in atopic dermatitis for infants as young as 3 months

Arcutis Biotherapeutics submitted a supplemental new drug application (sNDA) to the FDA seeking to expand the indication for Zoryve (roflumilast) cream 0.05% to include infants aged 3 months to younger than 24 months with mild to moderate atopic dermatitis.

The submission is supported by phase 1 pharmacokinetic data and the phase 2 INTEGUMENT-INFANT trial, which demonstrated clinically meaningful improvements in disease severity and pruritus over 4 weeks, with more than half of treated infants achieving Eczema Area and Severity Index–75 response and a favorable safety profile consistent with prior pediatric studies.

If approved, the label expansion would extend use of the once-daily, nonsteroidal topical therapy to a population with limited treatment options and build on its existing indication in children aged 2 years and older.